Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2018-A02624-51 | Registry Identifier | ID-RCB - ANSM |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Unexplained chronic hypereosinophilia (HE) and hypereosinophilic syndromes (HES) are heterogeneous regarding the organ involvements (heart, lungs, skin, .. or none), the evolutionary profiles, the response to treatments.
Underlying mechanisms are largely unknown and may associate genetic predisposing factors (germinal ? somatic?), environmental factors (alimentation, tobacco use, hormones, infections, ..) The COHESion study aims to study all clinical and biological characteristics of HE/HES patients and their evolutionary profiles, with a focus on genetic factors and the mechanisms supporting transitory or persistant chronic HE/HES (in absence of any well identified extrinsic trigger like drugs, parasitosis, ..)
There is currently no data on the natural history of unexplained chronic hypereosinophilia (HE) and hypereosinophilic syndromes (HES). Clinical practice shows that HE/SHE patients can present 4 evolutionary profiles:
A. a single flare-up of their disease, with favourable evolution spontaneously or under corticosteroid therapy, without further recurrence B. recurrent flare-ups with a variable free interval of several months to several years, with or without persistent eosinophilia between flare-ups C. a chronic disease requiring the continuation of a substantive treatment D. chronic asymptomatic HE for years: the mechanisms involved in the occurrence of possible organ damage are unknown
The primary objective of the study is to describe the frequency of the different clinical manifestations during the diagnostic and follow-up of the hypereosinophilic syndrome (HES). The primary endpoint is the frequency of the different clinical manifestations and/or organs damage related to eosinophilia.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Eosinophilia/Hypereosinophilic syndrome | patient with eosinophilia and/or hypereosinophilic syndrome |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Biological sample | Biological | Additional blood samples for biobanking |
|
| Measure | Description | Time Frame |
|---|---|---|
| Frequency of the different clinical manifestations at time of diagnosis and during follow-up of the hypereosinophilic syndrome (HES) | The primary objective of the study is to describe the frequency of the different clinical manifestations at diagnosis and during follow-up of the hypereosinophilic syndrome (HES/HE). The primary endpoint is the frequency of the different clinical manifestations and/or organs damage related to hypereosinophilia. | 10 years |
| Measure | Description | Time Frame |
|---|---|---|
| Frequency of the evolutionary profiles | Frequency of the different evolutionary profiles. | 10 years |
| Frequency of complications depending of the type of HES | Frequency of complications (organ damages) depending on the type of HES (idiopathic, reactive, clonal…). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Patients with Hypereosinophilia and Hypereosinophilic Syndromes
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Guillaume Lefevre, MD | Contact | 03 20 44 55 72 | +33 | Guillaume.lefevre@chru-lille.fr |
| Name | Affiliation | Role |
|---|---|---|
| Guillaume Lefevre | University Hospital, Lille | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hôpital Roger Salengro, CHU | Recruiting | Lille | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39757773 | Result | Lefevre G, Bleuse S, Puyade M, Moulis G, Neel A, Abisror N, Baudet A, Bonnotte B, Dion J, Dossier A, Grall M, Lifermann F, Limal N, Lioger B, Machelart I, Mohr C, Outh R, Queyrel-Moranne V, Slama B, Trefond L, Abou Chahla W, Ackerman F, Belfeki N, Berezne A, Blade JS, Bouderbala MA, Chebrek S, Cottin V, De Almeida S, De Masson A, Dezoteux F, Goulenok T, Jachiet V, Jouvray M, Latu I, Ledoult E, Leurs A, Lugosi M, Martin M, Melboucy-Belkhir S, Morati-Hafsaoui C, Quemeneur T, Rohmer J, Roy-Peaud F, Sanges S, Schleinitz N, Staumont-Salle D, Taille C, Terriou L, Tieulie N, Koenga JDE, Schwarb L, Panel K, Kahn JE, Groh M; COHESion study group. Hypereosinophilia and Hypereosinophilic Syndromes: First Findings From a Nationwide Multicenter Cohort. Allergy. 2025 Apr;80(4):1100-1110. doi: 10.1111/all.16463. Epub 2025 Jan 5. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D004802 | Eosinophilia |
| D017681 | Hypereosinophilic Syndrome |
| ID | Term |
|---|---|
| D007960 | Leukocyte Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood.
| 10 years |
| Frequency of organ damage profiles before and after 18 years old. | Describe the characteristics of pediatrics HE/HES vs adult HE/HES. | 10 years |
| Frequency of clinical complications profiles before and after 18 years old. | Clinical characteristics of pediatrics HE/HES vs adult HE/HES. | 10 years |
| Frequency of HLA alleles and variants / mutations on other genes of HE/HES | Predisposing factors in HE/HES by various genomic approaches | 10 years |
| Serum biomarkers | to explore Potential predisposing factors in HE/HES: serum markers predictive of interest in eosinophilopoiesis (IL5), tissue homing (eotaxins, etc.) | 10 years |
| Difference in Membrane activation markers of HE patients (asymptomatic) versus SHE (symptomatic). | Predisposing factors in HE/HES by various genomic approaches | 10 years |
| Difference in Eosinophilic gene expression profiles of HE patients (asymptomatic) versus SHE (symptomatic). | Predisposing factors in HE/HES by various genomic approaches | 10 years |